Using the AMAP Risk Score to Predict Late Recurrence Following Radiofrequency Ablation for Hepatocellular Carcinoma in Chinese Population: A Multicenter Study

Overview

Journal J Hepatocell Carcinoma

Date 2021 Aug 5

PMID 34350139

Citations 4

Authors

Yi Yang

Yanzhao Zhou

Xinyuan Zhang

Yujing Xin

Yi Chen

Qingsheng Fan

Xiao Li

Xi Wei

Qiang Li

Xiang Zhou

Jinxue Zhou

Affiliations

Soon will be listed here.

Abstract

Objective: This study was conducted to explore the application of age-male-ALBI-platelets (aMAP) score for predicting late recurrence of hepatocellular carcinoma (HCC) following radiofrequency ablation (RFA) and develop an aMAP score based-nomogram to predict prognosis in Chinese population.

Materials And Methods: HCC patients who developed late recurrence following RFA at National Cancer Center (NCC) of China, First Hospital of Shanxi Medical University and Beijing Hospital of Traditional Chinese Medicine from January 2011 to December 2016 were included as a training cohort, and patients who were treated at Affiliated Cancer Hospital of Zhengzhou University between January 2012 and December 2016 were included as an external validation cohort. The optimal cut-off value for aMAP score was determined using X-tile software to discriminate the performance of recurrence-free survival (RFS).

Results: A total of 339 eligible patients were included in this study. Patients were grouped into low-risk (aMAP score ≤64.2), medium-risk (64.3 ≤aMAP score ≤68.6) and high-risk (aMAP score ≥68.7) groups by X-tile plots. The prognostic factors that affected RFS were the number of lesions and aMAP score. A nomogram was constructed to predict the RFS with a C-index of 0.793 (95% CI: 0.744-0.842). The time-dependent receiver operating characteristic curves (t-AUCs) of the nomogram to predict 3, 4 and 5-year RFS were 0.808, 0.820 and 0.764, respectively. The model was then tested with data from an external validation cohort. The calibration curve confirmed the optimal agreement between the predicted and observed values.

Conclusion: The aMAP score provided a well-discriminated risk stratification and is an independent prognostic factor for the late recurrence of HCC following RFA. The aMAP score-based nomogram could help to strengthen prognosis-based decision making and formulate adjuvant therapeutic and preventive strategies.

Citing Articles

Clinical Applications of Artificial Intelligence (AI) in Human Cancer: Is It Time to Update the Diagnostic and Predictive Models in Managing Hepatocellular Carcinoma (HCC)?.

Romeo M, Dallio M, Napolitano C, Basile C, Di Nardo F, Vaia P Diagnostics (Basel). 2025; 15(3).

PMID: 39941182 PMC: 11817573. DOI: 10.3390/diagnostics15030252.

Albumin-Bilirubin Grade as a Valuable Predictor of Recurrence and Prognosis in Patients with Hepatocellular Carcinoma Following Radiofrequency Ablation.

Lee C, You G, Jo H, Jun C, Cho E, Kim I Cancers (Basel). 2025; 16(24.

PMID: 39766066 PMC: 11674869. DOI: 10.3390/cancers16244167.

Assessing the Predictive Accuracy of the aMAP Risk Score for Hepatocellular Carcinoma (HCC): Diagnostic Test Accuracy and Meta-analysis.

Elgenidy A, Abubasheer T, Odat R, Abdelrahim M, Jibril N, Ramadan A J Clin Exp Hepatol. 2024; 15(1):102381.

PMID: 39262566 PMC: 11386263. DOI: 10.1016/j.jceh.2024.102381.

Hepatocellular Carcinoma Risk Scores from Modeling to Real Clinical Practice in Areas Highly Endemic for Hepatitis B Infection.

Hao X, Fan R, Zeng H, Hou J J Clin Transl Hepatol. 2024; 11(7):1508-1519.

PMID: 38161501 PMC: 10752803. DOI: 10.14218/JCTH.2023.00087.

Usefulness of aMAP Risk Score for Predicting Recurrence after Curative Treatment for Hepatocellular Carcinoma within Milan Criteria.

Ohama H, Hiraoka A, Tada F, Kato K, Fukunishi Y, Yanagihara E Oncology. 2023; 101(9):575-583.

PMID: 37459848 PMC: 10614485. DOI: 10.1159/000530987.

References

Laimer G, Schullian P, Jaschke N, Putzer D, Eberle G, Alzaga A . Minimal ablative margin (MAM) assessment with image fusion: an independent predictor for local tumor progression in hepatocellular carcinoma after stereotactic radiofrequency ablation. Eur Radiol. 2020; 30(5):2463-2472. PMC: 7160081. DOI: 10.1007/s00330-019-06609-7. View

Xia Y, Li J, Liu G, Wang K, Qian G, Lu Z . Long-term Effects of Repeat Hepatectomy vs Percutaneous Radiofrequency Ablation Among Patients With Recurrent Hepatocellular Carcinoma: A Randomized Clinical Trial. JAMA Oncol. 2019; 6(2):255-263. PMC: 6902111. DOI: 10.1001/jamaoncol.2019.4477. View

Ruzzenente A, Guglielmi A, Sandri M, Campagnaro T, Valdegamberi A, Conci S . Surgical resection versus local ablation for HCC on cirrhosis: results from a propensity case-matched study. J Gastrointest Surg. 2011; 16(2):301-11. DOI: 10.1007/s11605-011-1745-x. View

Zheng J, Chou J, Gonen M, Vachharajani N, Chapman W, Doyle M . Prediction of Hepatocellular Carcinoma Recurrence Beyond Milan Criteria After Resection: Validation of a Clinical Risk Score in an International Cohort. Ann Surg. 2017; 266(4):693-701. PMC: 8404085. DOI: 10.1097/SLA.0000000000002360. View

Xie D, Ren Z, Zhou J, Fan J, Gao Q . 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020; 9(4):452-463. PMC: 7423548. DOI: 10.21037/hbsn-20-480. View

Yang Y, Chen Y, Ye F, Cao X, Xin Y, Wang Y . Late recurrence of hepatocellular carcinoma after radiofrequency ablation: a multicenter study of risk factors, patterns, and survival. Eur Radiol. 2020; 31(5):3053-3064. DOI: 10.1007/s00330-020-07460-x. View

Yang Y, Ye F, Xin Y, Wang Y, Li X, Feng D . Prognostic significance of controlling nutritional status score-based nomogram for hepatocellular carcinoma within Milan criteria after radiofrequency ablation. J Gastrointest Oncol. 2020; 11(5):1024-1039. PMC: 7657839. DOI: 10.21037/jgo-20-225. View

Lencioni R, Crocetti L . Local-regional treatment of hepatocellular carcinoma. Radiology. 2011; 262(1):43-58. DOI: 10.1148/radiol.11110144. View

Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F . Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334(11):693-9. DOI: 10.1056/NEJM199603143341104. View

10.

Ahmed M, Solbiati L, Brace C, Breen D, Callstrom M, Charboneau J . Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. Radiology. 2014; 273(1):241-60. PMC: 4263618. DOI: 10.1148/radiol.14132958. View

11.

Yang Y, Xin Y, Ye F, Liu N, Zhang X, Wang Y . Early recurrence after radiofrequency ablation for hepatocellular carcinoma: a multicenter retrospective study on definition, patterns and risk factors. Int J Hyperthermia. 2021; 38(1):437-446. DOI: 10.1080/02656736.2020.1849828. View

12.

El-Serag H, Rudolph K . Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132(7):2557-76. DOI: 10.1053/j.gastro.2007.04.061. View

13.

Lee C, Lu S, Changchien C, Yeh C, HSU T, Tang J . Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer. 1999; 86(7):1143-50. DOI: 10.1002/(sici)1097-0142(19991001)86:7<1143::aid-cncr7>3.0.co;2-z. View

14.

Tsilimigras D, Bagante F, Moris D, Hyer J, Sahara K, Paredes A . Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria. Ann Surg Oncol. 2020; 27(7):2321-2331. DOI: 10.1245/s10434-020-08452-3. View

15.

Forner A, Reig M, Bruix J . Hepatocellular carcinoma. Lancet. 2018; 391(10127):1301-1314. DOI: 10.1016/S0140-6736(18)30010-2. View

16.

Zhou Y, Yang Y, Zhou B, Wang Z, Zhu R, Chen X . Challenges Facing Percutaneous Ablation in the Treatment of Hepatocellular Carcinoma: Extension of Ablation Criteria. J Hepatocell Carcinoma. 2021; 8:625-644. PMC: 8232857. DOI: 10.2147/JHC.S298709. View

17.

Liu W, Zheng Y, He W, Zou R, Qiu J, Shen J . Microwave vs radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Aliment Pharmacol Ther. 2018; 48(6):671-681. DOI: 10.1111/apt.14929. View

18.

White D, Thrift A, Kanwal F, Davila J, El-Serag H . Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. Gastroenterology. 2016; 152(4):812-820.e5. PMC: 5346030. DOI: 10.1053/j.gastro.2016.11.020. View

19.

Fan R, Papatheodoridis G, Sun J, Innes H, Toyoda H, Xie Q . aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Hepatol. 2020; 73(6):1368-1378. DOI: 10.1016/j.jhep.2020.07.025. View

20.

Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio G . Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006; 243(2):229-35. PMC: 1448919. DOI: 10.1097/01.sla.0000197706.21803.a1. View